Table 1.
Demographic and clinical baseline characteristics for patients with obstructive lung disease prescribed fine- versus extra-fine particle ICS.
Fig 1.
Probability (95% CI) of pneumonia in outcome period by treatment group.
Table 2.
Pneumonia diagnosis by treatment group.
Table 3.
ATS/ERS exacerbations in outcome period by treatment group.
Table 4.
Acute respiratory events in outcome period by treatment group.
Fig 2.
Probability (95% CI) of pneumonia in outcome period by average daily consumed ICS dose during outcome period.
Table 5.
Pneumonia diagnosis by average daily consumed ICS dose during outcome period.